Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) publication / By David Žihala
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs publication / By David Žihala
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials publication / By David Žihala
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment publication / By David Žihala
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies publication / By David Žihala
OMIP-117: 40-Parameter/37-Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients publication / By David Žihala
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma publication / By David Žihala
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis publication / By David Žihala
Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential publication / By David Žihala
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies publication / By David Žihala
